Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 months ago, its launch has progressed smoothly as the treatment has proven a worthy competitor to Pfizer’s powerhouse Vyndamax ...
An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ...
BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA ...
BridgeBio Pharma recently filed a New Drug Application with the FDA for encaleret in autosomal dominant hypocalcemia type 1, following Phase 3 CALIBRATE results showing rapid, durable improvements in ...
BBIO’s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer’s Tafamidis and Alnylam’s Amvuttra. Its US uptake keeps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results